We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A Modified MS2 Bacteriophage Plaque Reduction Assay for the Rapid Screening of Antiviral Plant Extracts
News

A Modified MS2 Bacteriophage Plaque Reduction Assay for the Rapid Screening of Antiviral Plant Extracts

A Modified MS2 Bacteriophage Plaque Reduction Assay for the Rapid Screening of Antiviral Plant Extracts
News

A Modified MS2 Bacteriophage Plaque Reduction Assay for the Rapid Screening of Antiviral Plant Extracts

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "A Modified MS2 Bacteriophage Plaque Reduction Assay for the Rapid Screening of Antiviral Plant Extracts"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Traditional methods of screening plant extracts and purified components for antiviral activity require up to a week to perform, prompting the need to develop more rapid quantitative methods to measure the ability of plant based preparations to block viral replication. We describe an adaption of an MS2 plaque reduction assay for use in S. aureus.


The ability of the MS2 plaque reduction assay to detect antiviral activity in these known antiviral plant preparations indicates its suitability as an antiviral screening tool. An advantage of this assay compared with traditionally used cytopathic effect reduction assays and replication based assays is the more rapid acquisition of results. Antiviral activity was detected within 24 h of the start of testing. The MS2 assay is also inexpensive and non-pathogenic to humans making it ideal for initial screening studies or as a stimulant for pathogenic viruses.


To read the full publication, please follow the link provided.

Advertisement